When putting together your watch list, look for stocks with an 80 or higher RS Rating. Harrow just met that criteria with a new score of 83.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary RS Rating measures technical performance by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the top-performing stocks often have an RS Rating north of 80 as they begin their biggest runs.
Harrow has climbed more than 5% past a 20.31 entry in a third-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company showed 0% earnings growth last quarter. Revenue gains came in at 38%.
Harrow earns the No. 105 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
